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Abstract
Summary This phase 2 study evaluated the efficacy and safety of transitioning to zoledronate following romosozumab treatment
in postmenopausal women with low bone mass. A single dose of 5 mg zoledronate generally maintained the robust BMD gains
accrued with romosozumab treatment and was well tolerated.
Introduction Follow-on therapy with an antiresorptive agent is necessary to maintain the skeletal benefits of romosozumab
therapy. We evaluated the use of zoledronate following romosozumab treatment.
Methods This phase 2, dose-finding study enrolled postmenopausal women with low bone mineral density (BMD). Subjects
who received various romosozumab doses or placebo from months 0–24 were rerandomized to denosumab (60 mg SC Q6M) or
placebo for 12 months, followed by open-label romosozumab (210 mg QM) for 12 months. At month 48, subjects who had
received active treatment for 48 months were assigned to no further active treatment and all other subjects were assigned to
zoledronate 5 mg IV. Efficacy (BMD, P1NP, and β-CTX) and safety were evaluated for 24 months, up to month 72.
Results A total of 141 subjects entered the month 48–72 period, with 51 in the no further active treatment group and 90 in the
zoledronate group. In subjects receiving no further active treatment, lumbar spine (LS) BMD decreased by 10.8% from months
48–72 but remained 4.2% above the original baseline. In subjects receiving zoledronate, LS BMD was maintained (percentage
changes: − 0.8% from months 48–72; 12.8% from months 0–72). Similar patterns were observed for proximal femur BMD in
both groups. With no further active treatment, P1NP and β-CTX decreased but remained above baseline at month 72. Following
zoledronate, P1NP and β-CTX levels initially decreased but approached baseline by month 72. No new safety signals were
observed.
Conclusion A zoledronate follow-on regimen can maintain robust BMD gains achieved with romosozumab treatment.
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Introduction
Osteoporosis is a chronic condition requiring long-term
therapy, potentially involving sequential treatment regimens
with different agents over a patient’s lifetime. Accumulating
evidence supports treatment strategies that improve and then
maintain bone mineral density (BMD) to desired goals, in
order to reduce fracture risk [1–4].
Antiresorptive drugs such as bisphosphonates and
denosumab may be given for several years. These agents
increase BMD but do not correct the deficits in trabecular
microarchitecture [5, 6]. Notably, therapies that stimulate bone
formation can quickly increase BMD and improve bone
structure [7]. Regulatory recommendations limit the use of
previously available anabolic agents, including the parathyroid
hormone (PTH) analogue teriparatide and the PTH receptor
agonist abaloparatide, to a combined 2 years of treatment in a
patient’s lifetime [8, 9]; thus, limiting the use of these drugs for
long-termmanagement of osteoporosis. Additionally, the BMD
gains achieved with teriparatide are lost upon discontinuing
therapy, but these gains can be preserved or amplified when
subjects are switched to alendronate or denosumab upon
stopping teriparatide therapy [10, 11]. Similarly, BMD gains
and fracture risk reduction observed with abaloparatide are
maintained upon transitioning to alendronate [12]. As a result,
current guidelines recommend following anabolic therapy with
a potent antiresorptive agent [13, 14].
Romosozumab is a monoclonal antibody that inhibits
sclerostin and has a dual effect of increasing bone formation
and decreasing bone resorption [15–17], and has also been
shown to improve skeletal microarchitecture [18, 19]. In the
first 24 months of this dose-finding phase 2 study in
postmenopausal women with low bone mass, we evaluated
the efficacy and safety of different romosozumab doses
(70 mg, 140 mg, and 210 mg) administered by subcutaneous
(SC) injection at 1- or 3-month intervals to identify the optimal
romosozumab regimen [17, 20]. Treatment with romosozumab
210 mg monthly (QM) for 12 months was subsequently shown
to significantly increase BMD and reduce fracture risk
compared to placebo and to alendronate in women with
postmenopausal osteoporosis in phase 3 studies [21, 22]. The
fracture protection benefit of romosozumab was maintained
during the subsequent interval of antiresorptive treatment. A
phase 3 open-label study also demonstrated the efficacy and
safety of romosozumab when administered to subjects
previously treated with bisphosphonates [23]. Romosozumab
has been approved in several countries, e.g., for the treatment of
osteoporosis in the USA [24] and for the treatment of severe
osteoporosis in the EU [25] in postmenopausal women at high
risk for fracture.
We extended the current phase 2 study to investigate the
effects of discontinuing romosozumab and switching to
denosumab or placebo from months 24 to 36, observing
that subjects receiving denosumab continued to accrue
BMD, whereas BMD returned toward baseline levels when
romosozumab was discontinued without follow-on therapy
[20]. These data pointed to the need for antiresorptive
follow-on therapy to maintain the large and rapid BMD
gains from romosozumab treatment. Phase 3 studies have
subsequently confirmed the efficacy of antiresorptive
therapy such as denosumab or alendronate following
romosozumab in both maintaining BMD and in preserving
the benefit of the initial treatment with romosozumab on
fracture risk [2, 21, 22].
In a prior extension of this phase 2 study, subjects received
a second course of romosozumab 210 mg QM from months
36 to 48. Rapid and large BMD gains with romosozumab
were observed in subjects who had received no active
treatment in the 12 months prior [26]. The BMD response to
romosozumab following denosumab was very small, but
romosozumab prevented BMD declines following denosumab
discontinuation. Recognizing the need for following
romosozumab therapy with an antiresorptive agent, in the last
stage of this phase 2 study, we evaluated the efficacy and safety
of a single dose of zoledronate (also known as zoledronic acid)
5 mg upon stopping treatment with the second course of
romosozumab. This report describes the results of this final
segment of the study.
Materials and methods
Study design
This phase 2, international, multicenter, randomized,
placebo-controlled, dose-finding, parallel-group study
enrolled postmenopausal women aged 55 to 85 years with
a low BMD (T-score of ≤ − 2.0 and ≥ − 3.5 at the lumbar
spine, total hip, or femoral neck) [17]. Key exclusion
criteria have been previously described [17] and are
provided in Online Resource Supplemental Methods.
Treatment groups in the romosozumab double-blind period
(months 0 to 24), denosumab extension period (months 24 to
36), romosozumab second-course period (months 36 to 48),
and zoledronate follow-on period (months 48 to 72) are
presented in Fig. 1; additional details of the study design have
been previously published [17]. Briefly, women were
randomized to receive 1 of 5 dosing regimens of SC
romosozumab or to receive 1 of 2 open-label comparators (oral
alendronate 70 mg weekly [QW] or SC teriparatide 20 μg
daily) (Fig. 1a). The remaining 52 women were randomly
assigned to receive placebo injections QM or Q3M.
On completing the 12-month double-blind treatment
period, subjects in the romosozumab and placebo groups
continued their assigned treatment for an additional 12months
[17, 20] (Fig. 1a). At month 24, eligible consenting subjects
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entered a 12-month extension phase and were rerandomized
(1:1) to double-blind treatment with placebo or denosumab
60 mg (Amgen Inc., Thousand Oaks, CA) every 6 months
(Q6M) (Fig. 1a). Subjects who completed the month 24 to
36 denosumab extension period entered a 12-month phase
where they received open-label romosozumab 210 mg
(Amgen Inc., Thousand Oaks, CA) QM through month 48
(romosozumab second-course period).
Subjects who completed the month 36 to 48 romosozumab
second-course period were then eligible to enter a 24-month
extension (month 48 to 72 follow-on period) where they were
assigned to either no further active treatment or to receive a
single intravenous (IV) dose of zoledronate 5 mg at month 48
(Fig. 1a, b). Eligibility for the month 48 to 72 follow-on
period was assessed by the investigator using a 3-step
approach with no randomization. Subjects were assigned to
no further active treatment if they (1) had been assigned to
active treatment (romosozumab any dose and schedule,
followed by denosumab 60 mg Q6M, and then followed by
romosozumab 210 mg QM) throughout the first 48 months;
(2) had no clinical vertebral or fragility fracture between
months 24 and 48; (3) had a BMD T-score > − 2.5 at the
Romosozumab 70 mg SC QM (N = 51)
Romosozumab 140 mg SC Q3M (N = 54)
Romosozumab 210 mg SC QM (N = 52)
Placebo QM (N = 30)
Romosozumab 140 mg SC QM (N = 51)
Romosozumab 210 mg SC Q3M (N = 53)
Placebo Q3M (N = 22)
120Month 24 36 48 72
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Fig. 1 Study schema. a Subjects were randomized 1:1:1:1:1:1:1:1 to the
first 24 months of treatment. Administration of placebo and the various
romosozumab doses was blinded; alendronate and teriparatide were
administered open-label. At month 24, subjects were rerandomized
(1:1) within treatment group to placebo or denosumab (60 mg SC
Q6M) for 12 months, followed by a 12-month second course of
romosozumab 210 mg QM. b For subjects who reached month 48 of
the study, eligibility for the month 48 to 72 zoledronate follow-on
period was assessed by the investigator using a 3-step approach with no
randomization. Subjects were assigned to no further active treatment if
they (1) had been assigned to active treatment throughout the first
48 months (romosozumab any dose and schedule, followed by
denosumab 60 mg Q6M, and then followed by romosozumab 210 mg
QM); (2) had no clinical vertebral or fragility fracture between months 24
and 48; (3) had a BMD T-score > − 2.5 at the lumbar spine, total hip, or
femoral neck at month 48; or (4) had any contraindication to zoledronate.
All other subjects were assigned to receive a single IV dose of zoledronate
5 mg. aSubjects transitioned to romosozumab 140 mg QM at month 12,
were randomized in the denosumab extension period, completed the
study at month 36, and are not included in the present analysis.
bSubjects completed the study at month 12 and are not included in the
present analysis. cOf the subjects randomized to romosozumab 210 mg
QM in the double-blind period, 12 entered the no further active treatment
group and 17 entered the zoledronate group during the follow-on phase.
IV intravenous, PO orally, QD every day, QM every month, Q3M every
3 months, QW every week, SC subcutaneous
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lumbar spine, total hip, and femoral neck at month 48; or (4)
had any contraindication to zoledronate. All other subjects
were assigned to zoledronate which was administered at
month 48, approximately 4 weeks after the month 47 dose
of romosozumab.
The study protocol was approved by an independent ethics
committee or institutional review board at each center, and
the study was registered as a clinical trial with registration
identification ClinicalTrials.gov NCT00896532. The study
was conducted in accordance with International Conference
on Harmonization guidelines on Good Clinical Practice and
the principles of the Declaration of Helsinki. All subjects
provided written informed consent.
Study procedures
The study procedures for assessing BMD, bone turnover
markers, and other measures during the first 48 months of
the study have been previously published [17, 20]. This report
describes BMD measured at the lumbar spine and proximal
femur by dual energy X-ray absorptiometry (Lunar, GE
Medical Systems, Madison, WI, USA or Hologic, Hologic
Inc., Bedford, MA, USA) at months 36, 39, 42, 48, 54, 60,
66, and 72. BioClinica (previously known as Synarc; Newark,
CA, USA) analyzed the scans and provided quality control of
the scans and scanners. Blood was collected and analyzed for
serum chemistry, hematology, bone turnover markers, and
antiromosozumab antibodies. Levels of the bone formation
marker procollagen type I N-terminal propeptide (P1NP;
UniQ P1NP RIA, Orion Diagnostica Oy, Espoo, Finland)
and the bone resorption marker β-isomer of the C-terminal
telopeptide of type I collagen (β-CTX; Serum CrossLaps
ELISA, Nordic Bioscience Diagnostics, A/S, Herlev,
Denmark) were assessed at months 36, 37, 39, 42, 45, 48,
51, 54, 60, 66, and 72. Serum levels of antiromosozumab
antibodies were assessed at months 36, 39, 42, 45, 48, and
51. Samples were tested for romosozumab neutralizing
activity in vitro in subjects who tested positive for binding
antibodies, as previously described [16]. Adverse events were
collected as observed by the investigator or reported by
subjects. Potential cases of osteonecrosis of the jaw and
atypical femoral fracture were adjudicated by independent
committees.
Study outcomes
Results of the study periods up to month 48 have been
previously published [17, 20, 26]. This report focuses on
results from the month 48 to 72 follow-on period, assessing
the exploratory endpoints of the percentage change in BMD
at the lumbar spine, total hip, and femoral neck and bone
turnover markers (P1NP and β-CTX), and the safety of
transitioning to zoledronate after 12 months of treatment with
a second course of romosozumab.
Statistical analysis
The efficacy set included subjects enrolled in the month 48 to
72 follow-on period, and data were analyzed according to the
treatment allocation as determined by the assigned treatment
sequence throughout the study. The safety set included all
subjects who were enrolled in the month 48 to 72 follow-on
period, and data were analyzed by treatment received rather
than by treatment assigned.
Changes in BMD and bone turnover markers were
summarized separately for subjects assigned to no further
active treatment and subjects assigned to zoledronate.
Subjects assigned to no further active treatment who began
receiving an alternative treatment for osteoporosis, as
determined by the investigator, were censored 3 months after
the start of the alternative treatment for BMD and at the start
of alternative treatment for bone turnover markers. All
endpoints were summarized descriptively. Percentage change
in BMD from month 48 at months 54, 60, 66, and 72 and
from the initial baseline (month 0) at months 48, 54, 60, 66,
and 72 are presented as means and 95% confidence intervals.
Percentage change in P1NP and β-CTX from month 48 at
months 51, 54, 60, 66, and 72 and from the initial baseline
(month 0) at months 51, 54, 60, 66, and 72 are presented as
medians and interquartile ranges.
Safety endpoints were summarized for subjects assigned to
no further active treatment and subjects assigned to
zoledronate using the safety analysis set for the month 48 to
72 follow-on period. For subjects assigned to no further active
treatment, the start of the month 48 to 72 follow-on period was
defined as the month 48 study visit, 4 weeks after the month
47 dose of romosozumab. All adverse events occurring on this
date until the end of study date were reported in the follow-on
period. For subjects assigned to zoledronate, the start of the
month 48 to 72 follow-on period was defined as the date of the
first dose of zoledronate. All adverse events that started on the
day of the first dose of zoledronate or later were attributed to
zoledronate and hence were reported in the follow-on period.
Adverse events were coded using the Medical Dictionary for
Regulatory Activities (MedDRA; version 18.1).
Results
Subject disposition
Subject disposition has been previously published for the
month 0 to 24 romosozumab double-blind period and the
month 24 to 48 extension period [17, 20], and is summarized
through month 72 in Online Resource Fig. S1 (which includes
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all the study phases). Of the 313 subjects randomized to
placebo (n = 52) and romosozumab (n = 261) in the month 0
to 24 romosozumab double-blind period, 167 entered the
month 36 to 48 romosozumab second-course period. Of those,
141 entered the month 48 to 72 zoledronate follow-on period.
A total of 51 of the 141 subjects who entered the follow-on
period met the eligibility criteria to be assigned to no further
active treatment. These include 1 subject who received placebo
in the month 0 to 24 romosozumab double-blind period and
was incorrectly assigned to no further active treatment in the
follow-on period and 4 subjects who were assigned to no
further active treatment but received alendronate for the
treatment of bone loss that developed during the follow-on
period. The remaining 90 subjects were assigned to receive a
single IV dose of zoledronate 5 mg at month 48. These include
2 subjects who were incorrectly assigned to receive zoledronate
and 3 subjects who were assigned to zoledronate but did not
receive investigational product frommonths 48 to 72. Of the 51
subjects assigned to no further active treatment, 50 (98.0%)
completed the month 48 to 72 follow-on period and 1 died
(Online Resource Fig. S1). Of the 90 subjects assigned to
zoledronate, 88 (97.8%) completed the month 48 to 72
follow-on period and 2 (2.2%) discontinued the study (1 after
the subject was determined to be ineligible; 1 after consent was
withdrawn) (Online Resource Fig. S1). All subjects enrolled in
the month 48 to 72 follow-on period were included in the safety
analysis except for the 3 subjects assigned to zoledronate who
did not receive the therapy.
Baseline characteristics
At the initial study baseline (month 0), demographic and key
characteristics were well matched between subject groups
entering the month 48 to 72 follow-on period (Table 1). At
month 48, the baseline for the month 48 to 72 follow-on period
reported here, subjects who had been on active treatment in the
previous 48 months and were therefore assigned to no further
active treatment in this follow-on period exhibited somewhat
higher BMD T-score values and levels of both bone turnover
markers than subjects assigned to zoledronate (Table 1). The
differences in BMD T-score values and levels of both bone
turnover markers between the groups might be due, in large
part, to the difference in the therapies received between the two
study groups during year 3 of the phase 2 study: the subjects
assigned to no further active treatment had received denosumab
Table 1 Baseline demographic and key characteristics for all subjects who entered the month 0 to 24 double-blind period and were assigned to no
further active treatment or zoledronate from months 48 to 72












5 mg IV single
doseb
(N = 90)
Age, mean (SD), years 67.2 (6.4) 65.8 (5.6) 71.8 (6.4) 70.3 (5.6)
BMD T-score, mean (SD)
Lumbar spine − 2.32 (0.54) − 2.34 (0.64) − 1.04 (0.88) − 1.28 (0.83)
Total hip − 1.63 (0.61) − 1.42 (0.61) − 1.29 (0.65) − 1.16 (0.63)
Femoral neck − 1.98 (0.54) − 1.86 (0.55) − 1.70 (0.56) − 1.63 (0.61)
Serum P1NP, median (Q1, Q3), μg/L 51.2 (37.4, 64.5) 49.9 (39.2, 60.8) 66.8 (51.0, 90.4) 46.7 (33.2, 54.3)
Serum β-CTX, median (Q1, Q3), ng/mL 0.54 (0.42, 0.65) 0.48 (0.37, 0.63) 0.55 (0.44, 0.82) 0.38 (0.30, 0.49)
N = number of subjects assigned to treatment groups from months 48 to 72
No further active treatment: Subjects randomized to romosozumab (any dose or schedule) in the month 0–24 double-blind period, received denosumab
60mg Q6M in the month 24–36 extension period, received a second course of romosozumab 210 mg QM frommonths 36 to 48, and received no further
active treatment from months 48 to 72
Zoledronate 5 mg IV single dose: Subjects randomized to romosozumab (any dose or schedule) or placebo in the month 0 to 24 double-blind period,
received denosumab or placebo in the month 24 to 36 extension period, received a second course of romosozumab 210 mg QM from months 36 to 48,
and received a single IV dose of zoledronate 5 mg from months 48 to 72
a Includes all subjects who enrolled in the month 48 to 72 follow-on phase assigned to no further active treatment including 1 subject who had been
randomized to placebo in the initial 24 months and was incorrectly assigned to no further active treatment
b Includes 2 subjects who were incorrectly assigned to zoledronate from months 48 to 72 and 3 subjects who were assigned to zoledronate at month 48
but did not receive treatment
β-CTX β-isomer of the C-terminal telopeptide of type I collagen, BMD bone mineral density, IV intravenous, P1NP procollagen type 1 N-terminal
propeptide, Q1 quartile 1, Q3 quartile 3, SD standard deviation
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during months 24 to 36 while almost all of the subjects in the
zoledronate group had received placebo during that interval.
Efficacy
Bone mineral density
BMD results for the overall population entering the month 48 to
72 follow-on period are presented in Fig. 2 and Online Resource
Table S1. In subjects assigned to no further active treatment
(n = 51), lumbar spine BMD decreased from months 48 to 72
(percentage change [95% CI]: − 10.8% [− 12.1, − 9.5]),
decreasing from a mean of 17.3% [15.2, 19.3] above initial
baseline value at months 48 to 4.2% [2.3, 6.1]) above the initial
baseline at month 72 (Fig. 2a, Online Resource Table S1). BMD
gains at the total hip and femoral neck for this group were also
reversed after romosozumab discontinuation. Total hip BMD
decreased from months 48 to 72 (percentage change [95%
CI]: − 6.4% [− 7.4, − 5.3]), and remained close to the initial
baseline level at month 72 (percentage change [95% CI] from
initial baseline: − 1.6% [− 2.8, − 0.3]) (Fig. 2b, Online Resource
Table S1). Femoral neck BMD decreased frommonths 48 to 72
(percentage change [95% CI]: − 5.9% [− 7.2, − 4.7]), and
remained close to the initial baseline level at month 72
(percentage change [95% CI] from initial baseline: − 1.2%
[− 2.6, 0.2]) (Fig. 2c, Online Resource Table S1).
In subjects assigned to zoledronate (n = 90), lumbar spine
BMD was maintained through months 48 to 72 (percentage
change [95% CI] from months 48 to 72: − 0.8% [− 1.6, 0];
percentage change [95% CI] from initial baseline to month
Fig. 2 Percentage change in BMD at the lumbar spine, total hip, and
femoral neck in all subjects who received romosozumab during months
36–48 and who were then assigned to no further active treatment (n = 51;
a–c) or zoledronate (n = 90; d–f) from months 48 to 72. Data are mean
(95% CI). BMD bone mineral density, CI confidence interval, DMAb
denosumab, QM every month, Q6M every 6 months
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72: 12.8% [11.4, 14.3]) (Fig. 2d, Online Resource Table S1).
Results for total hip and femoral neck also showed a similar
pattern to results observed for the lumbar spine. Total hip BMD
was maintained through months 48 to 72 (percentage change
[95% CI] from month 48: 0.1% [− 0.5, 0.7]; percentage change
[95% CI] from initial baseline to month 72: 4.2% [3.1, 5.3])
(Fig. 2e, Online Resource Table S1). Femoral neck BMD was
maintained through months 48 to 72 (percentage change [95%
CI] from month 48: 0.5% [− 0.4, 1.3]; percentage change [95%
CI] from initial baseline to month 72: 4.4% [3.0, 5.8]) (Fig. 2f,
Online Resource Table S1).
Bone turnover markers
P1NP and β-CTX results for the overall population entering
the month 48 to 72 follow-on period are presented in Fig. 3
and Online Resource Table S2. In subjects assigned to no
further active treatment frommonths 48 to 72 (n = 51), median
P1NP initially decreased but stayed above the initial baseline
level until month 72, and median β-CTX increased initially
then gradually decreased but remained above the initial
baseline level until month 72 (Fig. 3a, b, Online Resource
Table S2). In subjects assigned to zoledronate from months
48 to 72 (n = 90), median P1NP and β-CTX levels decreased
but thenmoved toward initial baseline level bymonth 72 (Fig.
3c, d, Online Resource Table S2).
Subgroup analysis
In the subpopulation of 29 subjects (no further active treatment
[n = 12]; zoledronate [n = 17]) who received romosozumab
210 mg QM during the first 24 months of the study, changes
in BMD and bone turnover markers during the month 48 to 72
follow-on period were consistent with changes observed in the
overall population (data not shown).
Safety
A summary of adverse events reported from months 48 to 72
is provided in Table 2. No subject discontinued investigational
product or study due to an adverse event. There were no
deaths in the zoledronate group versus 1 death in the no further
active treatment group. No adverse events of hypocalcemia,
hyperostosis, clinical vertebral fractures, adjudicated
osteonecrosis of the jaw, or adjudicated atypical femoral
fracture were reported in either treatment group. Fractures
occurred in 4 subjects in the no further active treatment group
and 2 subjects in the zoledronate group. Additional details of
Fig. 3 Percentage change in P1NP and β-CTX in all subjects who
received romosozumab during months 36–48 and who were then
assigned to no further active treatment (n = 51; a, b) or zoledronate (n =
90; c, d) from months 48 to 72. Data are median (Q1, Q3). β-CTX
β-isomer of the C-terminal telopeptide of type I collagen, DMAb
denosumab, IV intravenous, P1NP procollagen type I N-terminal
propeptide, Q1 quartile 1, Q3 quartile 3, QM every month, Q6M every
6 months
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the safety assessment from months 48 to 72 are presented in
the Online Resource Supplemental Results: Additional Safety.
Discussion
Our study demonstrates that a single 5 mg dose of
zoledronate preserves BMD for up to 2 years after stopping
romosozumab and provides further insights into the potential
treatment sequence with romosozumab. Simply stopping
romosozumab, even after very large BMD gains, resulted
in a decrease in BMD to levels slightly above (lumbar spine)
or near (total hip) baseline. The BMD loss after stopping a
12-month course of romosozumab presented here is
consistent with that previously reported after 2 years of
romosozumab treatment [20]. In contrast, a single dose of
IV zoledronate 5 mg generally maintained the BMD gains
achieved after a second course of romosozumab 210 mg
QM during months 36 to 48 at the lumbar spine and
proximal femur.
The efficacy of a single dose of zoledronate over an
interval of 24 months is consistent with previous studies
demonstrating a long duration of the effect of zoledronate
in preserving bone density [27–29]. Results from our study
are also consistent with results from previous studies
demonstrating the effectiveness of bisphosphonate therapy
to prevent bone loss upon stopping estrogen, denosumab,
or PTH receptor agonists [11, 12, 27, 30–32].
The findings from our study should be considered in the
context of several limitations including the small sample sizes
of the two treatment groups, short study follow-up periods,
and use of surrogate outcomes (percentage changes in BMD
and bone turnover markers) for efficacy evaluation.
Additionally, we evaluated the effect of only the single 5 mg
dose of zoledronate administered approximately 4 weeks after
the last dose of romosozumab. However, the major strength of
this phase 2 study, overall, is that it has provided safety and
Table 2 Incidence of adverse events from months 48 to 72
No further active treatment
(N = 51)a
n (%)




All adverse events 37 (72.5) 73 (83.9)
Serious adverse events 8 (15.7) 12 (13.8)
Death 1 (2.0) 0
Leading to study discontinuation 0 0
Adverse events of interest
Osteoarthritis 5 (9.8) 7 (8.0)
Potentially associated with hypersensitivity 3 (5.9) 3 (3.4)
Malignancies 0 2 (2.3)
Hyperostosis 0 0
Hypocalcemia 0 0
Osteonecrosis of the jawc 0 0
Atypical femoral fracturec 0 0
Fragility fractured 2 (3.9) 2 (2.3)
N = number of subjects in follow-on phase who did or did not receive at least 1 dose of zoledronate
n = number of subjects reporting at least 1 event
No further active treatment: Subjects randomized to romosozumab (any dose or schedule) in the month 0 to 24 double-blind period, received denosumab
60 mg Q6M in the month 24 to 36 extension period, received a second course of romosozumab 210 mg QM from months 36 to 48, and received no
further active treatment from months 48 to 72
Zoledronate 5 mg IV single dose: Subjects randomized to romosozumab (any dose or schedule) or placebo in the month 0 to 24 double-blind period,
received denosumab or placebo in the month 24 to 36 extension period, received a second course of romosozumab 210 mg QM from months 36 to 48,
and received a single IV dose of zoledronate 5 mg from months 48 to 72
a Includes all subjects who enrolled in the month 48 to 72 follow-on phase assigned to no further active treatment (including 1 subject who had been
randomized to placebo in the initial 24 months and was incorrectly assigned to no further active treatment)
b Data not shown for 3 subjects who were assigned to zoledronate at month 48 but did not receive treatment
c Potential cases of osteonecrosis of the jaw and atypical femoral fracture were adjudicated by independent committees
d No further active treatment group: 1 radius and 1 fibula fracture; zoledronate group: 1 radius and 1 rib fracture
IV intravenous, QM every month, Q6M every 6 months
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efficacy data for up to 2 consecutive years of treatment with
romosozumab in postmenopausal women with low bone
mass, information on the effects of stopping romosozumab
therapy, and information on a second course of romosozumab
treatment as well as clinically relevant patterns of using the
antiresorptive agents denosumab and zoledronate following
romosozumab therapy.
Osteoporosis is a chronic disease requiring life-long
management. Since all currently available osteoporosis therapies
are reversible over variable time frames, there is a need to
understand the proper sequence of treatments as romosozumab
is incorporated into osteoporosis management. Recent studies
demonstrate that therapy with anabolic or bone-forming agents
that increase bone formation by stimulation of osteoblasts such as
romosozumab, teriparatide, and abaloparatide in women with
postmenopausal osteoporosis is more effective in reducing
fracture risk than therapy with oral bisphosphonates [12, 21,
22, 33]. This has led expert opinion to suggest that the treatment
sequence of a bone-forming agent, followed by a potent
antiresorptive agent, be used more often to treat patients at high
risk for fracture [34, 35]. Our current study provides additional
evidence that transitioning patients from a treatment with
romosozumab to a potent antiresorptive, in this case zoledronate,
can maintain the robust BMD gains accrued with romosozumab
treatment, similar to what has previously been demonstrated for
denosumab and alendronate [21, 22]. There are no clear
guidelines for choosing among these antiresorptive agents to
follow romosozumab. That decision will depend upon the
clinical characteristics of the patients and concerns about side
effects and adherence to the various follow-on therapies.
In conclusion, the treatment sequence of romosozumab for
12 months followed by zoledronate preserves BMD for up to
2 years, is well tolerated, and is an option for patients with
osteoporosis at high risk for fracture.
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